SB2-G31-RA: Phase 3 SB2 compared to Remicade in Rheumatoid Arthritis

• Research type

  Research Study

• Full title

  A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy

• IRAS ID

  130605

• Contact name

  Christopher Edwards

• Contact email

  cedwards@soton.ac.uk

• Sponsor organisation

  Samsung Bioepis Co., Ltd.

• Eudract number

  2012-005733-37

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0280

• Date of REC Opinion

  26 Jun 2013

• REC opinion

  Favourable Opinion